A
Amy Chadburn
Researcher at NewYork–Presbyterian Hospital
Publications - 76
Citations - 8923
Amy Chadburn is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Lymphoma & T cell. The author has an hindex of 34, co-authored 76 publications receiving 8452 citations. Previous affiliations of Amy Chadburn include New York University & Cornell University.
Papers
More filters
Journal ArticleDOI
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
TL;DR: These findings indicate that NHL B cells deregulate an otherwise physiological autocrine survival pathway to evade apoptosis, and neutralization of BAFF and APRIL by soluble TACI and BCMA decoy receptors could be useful to dampen the accumulation of malignant B cells in NHL patients.
Journal ArticleDOI
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Jia Ruan,Peter Martin,Richard R. Furman,Shing M. Lee,Ken Cheung,Julie M. Vose,Ann S. LaCasce,Julia Morrison,Rebecca Elstrom,Scott Ely,Amy Chadburn,Ethel Cesarman,Morton Coleman,John P. Leonard +13 more
TL;DR: Bortezomib with R-CHOP-21 can be safely administered and may enhance outcomes, particularly in non-GCB DLBCL, justifying randomized studies and IPI and MIPI correlated with survival inDLBCL and MCL.
Journal ArticleDOI
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.
Till Strowig,Cagan Gurer,Alexander Ploss,Yi-Fang Liu,Frida Arrey,Junji Sashihara,Gloria C. Koo,Gloria C. Koo,Charles M. Rice,James W. Young,Amy Chadburn,Jeffrey I. Cohen,Christian Münz,Christian Münz +13 more
TL;DR: It is demonstrated that primary T cell responses in mice with reconstituted human immune system components control infection with the oncogenic and persistent Epstein-Barr virus.
Journal ArticleDOI
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma
John P. Leonard,Morton Coleman,Jamie C. Ketas,Amy Chadburn,Scott Ely,Richard R. Furman,William A. Wegener,Hans J. Hansen,Heather Ziccardi,Michael Eschenberg,Urte Gayko,Alessandra Cesano,David M. Goldenberg +12 more
TL;DR: A 43% objective response rate in follicular NHL patients treated at 360 mg/m2/wk indicates that this dose should be explored in additional studies, and well tolerated epratuzumab was well tolerated at up to 1,000mg/m 2/wk (for 4 weeks) and had clinical activity.
Journal ArticleDOI
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
Andrew M. Evens,Kevin A. David,Irene Helenowski,Beverly P. Nelson,Dixon B. Kaufman,Sheetal Mehta Kircher,Alla Gimelfarb,Elise Hattersley,Lauren Mauro,Borko Jovanovic,Amy Chadburn,Patrick J. Stiff,Jane N. Winter,Jayesh Mehta,Koen van Besien,Stephanie A. Gregory,Leo I. Gordon,Jamile M. Shammo,Scott E. Smith,Sonali M. Smith +19 more
TL;DR: In this paper, the authors examined the clinical features and outcomes among a large cohort of solid organ transplantation-related patients with PTLD who were recently treated at four Chicago institutions (from January 1998 to January 2008).